News
FDA Commissioner Marty Makary suggests his agency may expedite drug reviews for manufacturers reducing U.S. prices to global ...
50m
InvestorsHub on MSNCapricor Shares Tumble After FDA Rejects Duchenne Therapy ApplicationCapricor Therapeutics (NASDAQ:CAPR) saw its stock plummet by 53% on Friday after the U.S. Food and Drug Administration issued a Complete Response Letter (CRL), rejecting the company’s bid for approval ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results